UVA Health | Strategic Alliance Partners

Anita Clayton, MD, reviews the available phase 2 and 3 clinical data for the novel, once-daily oral investigative drug.

Investigator Anita Clayton, MD, shares insights into the new vortioxetine data and its implications for patients with depression and treatment-emergent sexual dysfunction.

Along with sports cardiology and pediatric cardiology, Robert Battle specializes in treating patients with hypertrophic cardiomyopathy, the most common genetic cardiovascular disorder.

A supplemental new drug application (sNDA) for vortioxetine (TRINTELLIX), a prescription medication for the treatment of adults with major depressive disorder (MDD), has been accepted by the FDA.

The heart rhythm specialist with the UVA Advanced Imaging group discussed his team's early successes with Medtronic's heart ablation vest.